Navigation Links
Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
Date:9/25/2008

rward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, product performance, competitive offerings, procedural volume, overall market size and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, con
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientific to Participate in UBS Global Life Sciences Conference
2. Boston Scientific Announces Court Decision
3. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
4. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
5. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
6. TechCFO Adds Gary Strickland as Partner in Boston Office
7. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
8. Boston Scientific To Webcast Conference Call Discussing Second Quarter Financial Results
9. Boston Scientific Welcomes Revised Outlook From Fitch Ratings
10. Boston Scientific to Participate in Goldman Sachs Conference
11. Boston Scientific Announces CEO Jim Tobin to Extend Tenure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YARDLEY , Pennsylvanie, 18 septembre 2014 ... Lyon en 1974, a été ... à compléter les évaluations cliniques traditionnelles par ... Reported Outcomes) et sur les impacts économiques ... http://photos.prnewswire.com/prnh/20140618/119365 A cours ...
(Date:9/18/2014)... OMICS Group International invites researchers, authors and academicians ... Access Week’ by actively contributing their research outcome ... from 20-26th October, 2014. , Pharmaceutical Sciences ... with a tremendous speed to provide improved medical ... is gearing with innovation and technological revolution to ...
(Date:9/18/2014)... a group of rare diseases that afflict skeletal ... onset hits at the fetal stage and is ... gene encoding fibroblast growth factor receptor 3 (FGFR3) ... dysplasia, thanatophoric dysplasia (TD), a skeletal dysplasia that ... often lethal, and achondroplasia (ACH), which causes stunted ...
(Date:9/18/2014)... Artificial sweeteners, promoted as aids to weight loss and ... intolerance and metabolic disease; and they do it in ... of the gut microbiota the substantial population of ... of experiments in mice and humans, were published today ... Eran Elinav of the Weizmann Institute,s Immunology Department, who ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... until further notice, RICHMOND, Va., Oct. 21 Insmed ... that on Thursday, October 16, 2008 NASDAQ issued a notice ... the enforcement of the rules ... Effective immediately, NASDAQ has also suspended the enforcement of the ...
... SAN DIEGO, Oct. 21 Althea Technologies, ... technologies for pharmaceutical,development and manufacturing, announced today ... as its President and Chief Executive Officer. ... Services (PDS) at,Patheon, Inc., will lead Althea,s ...
... Calif., Oct. 21 (11:00 PM PT,Oct. 20) ... announced that,Novartis AG has agreed to acquire from ... for $115 million in cash., "This agreement ... the development,of novel therapeutics using our PEGylation and ...
Cached Biology Technology:Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule 2Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule 3Althea Technologies Appoints Dr. Shabbir Anik as Chief Executive Officer 2Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 2Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 3Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 4
(Date:9/18/2014)... matter how many times it,s demonstrated, it,s still ... , But by using a signaling system ... their behavior to suit their population. In short, ... present, and act accordingly. , Once the population ... change from innocuous to pathogenic, or from unhelpful ...
(Date:9/18/2014)... Sept. 18, 2014 -- Arizona turned its newborn screening program ... few short months, earning it the first-ever Newborn Screening Quality ... of Dimes presented Will Humble, M.P.H., Arizona,s Department of Health ... today. Mr. Humble established a policy of full transparency for ... newborn blood samples to the lab for analysis, and set ...
(Date:9/18/2014)... global cycles of carbon and nitrogen comprise all ... and environmental systems have caused imbalances and perturbations ... gases (GHGs). Increased GHGs result in climate changes ... ecosystems, oceans and the atmosphere. Understanding these feedback ... branch of environmental science during the past three ...
Breaking Biology News(10 mins):Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Greenhouse gas research enters a new era 2
... NJIT Distinguished Professor Philip R. Goode and the Big Bear ... a deformable mirror in what is called adaptive optics ... an image of a sunspot was published yesterday on the ... day: http://www.cieletespace.fr/node/5752 "This photo ...
... With children going back to school, parents are concerned that ... who dine in a school cafeteria. New research funded ... eat school lunches that are part of the federal government,s ... The same research study found, however, that children who ...
... to locate and identify a gene responsible for a fatal ... may be responsible for a similar rare, fatal disease in ... of the disease in dogs and is the first step ... Dr. Natasha Olby, associate professor of neurology, was part ...
Cached Biology News:See amazing new sun images from NJIT's Big Bear Solar Observatory 2USDA-backed study finds federal school lunches linked to childhood obesity 2USDA-backed study finds federal school lunches linked to childhood obesity 3Researchers find gene responsible for neurodegenerative disease in dogs, possibly in humans 2
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: